[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100408293":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":13,"centralContacts":17,"locations":22,"responsibleParty":41,"collaborators":43,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"University of Colorado, Denver","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"Transgender",null,{"label":12,"type":10,"description":10,"interventionNames":10},"Cisgender",[14],{"name":15,"affiliation":5,"role":16},"Natalie Nokoff, MD, MSCS","PRINCIPAL_INVESTIGATOR",[18],{"name":15,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","720-777-3607","Natalie.Nokoff@childrenscolorado.org",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Children's Hospital Colorado","RECRUITING","Aurora","Colorado","80045","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-104.83192,39.72943,{"lat":35,"lon":34},[38],{"name":39,"role":19,"phone":20,"phoneExt":10,"email":40},"Natalie Nokoff, MD","natalie.nokoff@childrenscolorado.org",{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[44],{"name":45,"class":46},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100408293",false,"NCT04596592","Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth","PUBERTY","Inclusion Criteria (transgender females):\n\n* Identify as a transgender female\n* Age 13-16 years at the time of enrollment\n* If on a gonadotropin releasing hormone analogue, \\> 6 months exposure\n* Plan to start estradiol clinically in \\\u003C 4 months\n\nInclusion Criteria (cisgender males and females):\n\n* Males and females ages 13-16 years\n\nExclusion Criteria:\n\n* Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures\n* Antipsychotic medication use\n* Type 1 or 2 diabetes (by medical history)\n* Polycystic ovarian syndrome (PCOS for cisgender females)\n* Hypertension (resting BP ≥ 140\u002F90 mm\u002FHg)\n* Weight\\> 400 lbs\n* On oral progesterone medications (including oral progesterone or progestin, combined oral contraceptives or etonogestrel implant)\n* Pregnancy (for cisgender females)","ALL","13 Years","16 Years",{"count":57,"type":58},90,"ESTIMATED","OBSERVATIONAL","To evaluate the effect of estradiol with or without a prior gonadotropin releasing hormone analogue on insulin sensitivity and vascular function in transgender females compared to cisgender controls.",[62,63,64],"Transgenderism","Gender Dysphoria","Insulin Sensitivity","2025-06-05",{"date":67,"type":68},"2025-06-10","ACTUAL",{"date":70,"type":68},"2021-02-15",{"date":72,"type":58},"2026-07-31",{"name":5,"class":6},1]